Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

被引：7
|
作者：
Sorel, Nathalie
Roy, Lydia
Martineau, Geraldine
Guilhot, Francois
Turhan, Ali G.
Chomel, Jean-Claude
机构：
[1] CHU Poitiers, Lab Hematol, F-86021 Poitiers, France
[2] CHU Poitiers, EA 3805, F-86021 Poitiers, France
来源：
BLOOD | 2006年 / 108卷 / 05期
关键词：
D O I：
10.1182/blood-2006-03-011668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1782 / 1783
页数：2
相关论文
共 50 条
  • [1] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [2] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [3] Nilotinib reduces emergence of BCR–ABL mutations in CML
    Vanessa Marchesi
    Nature Reviews Clinical Oncology, 2013, 10 (5) : 248 - 248
  • [4] Bcr-Abl kinase inhibition as the basis of therapy for CML
    Druker, BJ
    Talpaz, M
    Resta, D
    Peng, B
    Buchdunger, E
    Ford, J
    Sawyers, CL
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 130 - 130
  • [5] BCR-ABL kinase mutations in response to dasatinib
    Khorashad, J. Sorouri
    Mehta, P.
    Milojkovic, D.
    Marin, D. C.
    Kaeda, J. S.
    Swale, B.
    Stevens, D.
    Goldman, J. M.
    Apperley, J. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 202 - 202
  • [6] Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Afsar Ali Mian
    Anna Metodieva
    Susanne Badura
    Mamduh Khateb
    Nili Ruimi
    Yousef Najajreh
    Oliver Gerhard Ottmann
    Jamal Mahajna
    Martin Ruthardt
    BMC Cancer, 12
  • [7] Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    Mian, Afsar Ali
    Metodieva, Anna
    Badura, Susanne
    Khateb, Mamduh
    Ruimi, Nili
    Najajreh, Yousef
    Ottmann, Oliver Gerhard
    Mahajna, Jamal
    Ruthardt, Martin
    BMC CANCER, 2012, 12
  • [8] BCR-ABL targeted therapy in chronic myeloid leukemia (CML).
    Goldman, JM
    Deininger, M
    Melo, JV
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 515 - 515
  • [9] Analysis of mutations in the BCR-ABL TK domain in CML patients
    Nesslboeck, M.
    Preuner, S.
    Lion, T.
    KLINISCHE PADIATRIE, 2010, 222 (03): : 217 - 217
  • [10] Characterization of the BCR-ABL kinase domain mutations in CML patients failing imanitib therapy
    Kuo, F. C.
    Kuo, C.
    Sholl, L.
    Longtine, J. A.
    LABORATORY INVESTIGATION, 2007, 87 : 249A - 249A
12345